TVM Capital Life Science

What TVM Capital Life Science does

TVM Capital Life Science is a dedicated life science venture capital firm founded in 1983, headquartered in Munich, Germany, with a second office in Montreal, Canada. The firm invests in clinical-stage biopharmaceutical, medtech, and diagnostic companies, providing growth capital alongside strategic support spanning regulatory navigation and commercialization. Its investment model is a traditional sector-specialized VC approach — deploying capital from limited partners into portfolio companies, generating returns through exits and carried interest, with management fees as the recurring revenue base.

The firm's identifiable portfolio is concentrated in medical imaging and diagnostics. Kent Imaging, a Calgary-based near-infrared spectroscopy medical imaging company, has achieved FDA clearance (2017) and CE Marking (2025) under TVM's backing and has launched the SnapshotGLO product. Smart Reporting, another portfolio company, acquired Fluency for Imaging to form Jacobian, an AI-powered radiology reporting and workflow entity processing approximately 80 million exams annually. The firm also previously acquired ImmunoRx Pharma in January 2021, extending its clinical-stage biopharmaceutical exposure.

Day-to-day leadership rests with managing partners Luc Marengere and Hubert Birner, supported by associates including Catello Somma and Dr. Valentina Agostoni. The firm's competitive positioning is built on cross-Atlantic deal flow between Europe and North America, a long-dated track record in life science investing, and active portfolio management — including orchestrating intra-portfolio M&A such as the formation of Jacobian. No information is disclosed regarding current AUM, fund vintages, revenue, or limited partner composition, which constrains financial benchmarking.

Name

TVM Capital Life Science

Website

https://tvm-lifescience.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

11–50 employees

Short description

TVM Capital Life Science is a Munich- and Montreal-based venture capital firm founded in 1983 that invests in clinical-stage biopharmaceutical, medtech, and diagnostic companies, with a portfolio spanning medical imaging (Kent Imaging), AI radiology (Smart Reporting/Jacobian), and biopharma (ImmunoRx Pharma).

Ownership category

akta.pro rank

Product category

Venture Capital (Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Investment Activities (5239)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industries

Late-Stage Venture Capital (Series C+) (FSANAAAC), Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Life sciences venture capital
• Healthcare equity investment
• Biotech growth capital
• Medtech venture funding
• Clinical-stage investment

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Core offering

TVM Capital Life Science is a dedicated life sciences venture capital firm that invests equity capital in clinical-stage biopharmaceutical, medtech, and diagnostic companies. Beyond capital, the firm provides strategic support to portfolio companies across regulatory navigation, commercialization, and inorganic growth initiatives such as M&A. It is headquartered in Munich, Germany with a North American office in Montreal, Canada, and has been operating since 1983.

Product overview

TVM Capital Life Science is a venture capital firm specializing in life sciences investments, particularly in healthcare and biotechnology sectors. As an investment company, it does not develop its own products; rather it provides funding and support to portfolio companies. Notable portfolio companies mentioned in available sources include Smart Reporting (acquiring Fluency for Imaging to form Jacobian™) and Kent Imaging (with SnapshotNIR and SnapshotGLO medical imaging products). No unified product platform information is available from the source data.

Differentiator

Problem solved

Functional benefit

Products and services

• Life Sciences Venture Capital Investment
• Portfolio Company Strategic Support

Quantifiable outcome

• Smart Reporting (portfolio company) processes approximately 80 million exams annually after acquisition of Fluency for Imaging to form Jacobian™
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• New Horizon Medical SolutionsminorStrategic or Co-development PartnerKent Imaging entered into a partnership with New Horizon Medical Solutions, expanding distribution and market reach for its medical imaging technology products.

Recent moves7 records

Expansion highlights4 records

Direct peers

• Forbion: European-based venture capital firm dedicated to life sciences investing across biotech and medtech. Directly comparable as a specialist healthcare VC with a similar transatlantic investment mandate and stage focus.
• Abingworth: Transatlantic life sciences investment firm backing clinical-stage biopharma and medtech companies. Highly comparable given overlapping geographic footprint (Europe/US), sector focus, and investment stage profile.
• Versant Ventures: Dedicated healthcare and life sciences venture firm with a North American base investing across biotech, medtech, and diagnostics. Comparable in sector specialization and clinical-stage focus.
• 5AM Ventures: Early-stage life sciences venture firm focused on biotech and platform technologies. Comparable as a specialist life sciences VC with similar stage orientation and portfolio construction approach.
• SV Health Investors: Transatlantic life sciences venture capital firm investing across biotech and medtech. Directly comparable given dual-region presence, healthcare specialization, and clinical-stage investment focus.
• Atlas Venture: Early-stage biotech venture firm focused on building new therapeutics companies. Comparable as a specialist life sciences VC with similar stage orientation, though with a stronger bias toward company formation rather than late-stage clinical investing.

Broad incumbents

• OrbiMed: One of the largest dedicated healthcare investment firms globally, spanning venture, growth, and public equities across biopharma, medtech, and diagnostics. Comparable sector mandate but materially larger AUM and broader investment stage coverage.
• Novo Ventures: Life sciences venture arm of the Novo Nordisk Foundation investing globally in biopharma and biotech. Comparable in life sciences specialization, but operates with significantly larger capital base and broader geographic reach.
• SR One (GSK): Healthcare-focused venture firm affiliated with GSK investing in biopharma and medtech. Comparable sector specialization with the added backing of a strategic corporate parent providing larger patient capital.

Regional players

• Life Sciences Partners (LSP): European life sciences-focused venture and growth capital firm investing in medical, biotech, and pharmaceutical companies. Comparable sector mandate and stage orientation, but with a primarily European geographic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/tvmcapital
• LinkedInlinkedin.com/company/tvm-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments25 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TVM Capital Life Science